Mihaela Aldea, Medical Oncologist at the Gustave Roussy, shared a post on X:
“New from the RET-MAP registry
What happens when patients with RET+ NSCLC are retreated with a same-class selective RET inhibitor?
Among 41 patients:
- Switch after toxicity – ORR 67%, mPFS 9.9m. Effective, but toxicity often recurs – monitor closely and consider starting at lower doses
- Rechallenge after progression – modest overall, signal with selpercatinib in isolated CNS progression on pralsetinib or oligoprogression
- Bypass combos (mostly MET amp) – ORR 39%, mPFS 4m, benefit mainly in patients with prior durable response”
Title: Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib – Results from the RET-MAP Registry
Authors: Arianna Marinello, Julia K. Rotow, Meghanne Lomibao, Daniela Miliziano, Rita Leporati, Jamie Feng, Giulio Metro, Mariana Brandão, Teresa Gorría, Amin H. Nassar, Fabrizio Citarella, Matteo Fila, Vincent Fallet, Biagio Ricciuti, Skyler Taylor, Jordi Remon, David Planchard, Narjust Florez, Benjamin Besse, Alexander Drilon, Mihaela Aldea.
Other articles featuring Mihaela Aldea on OncoDaily.